Crizotinib (Xalkori®) Managed Entry Scheme for listing on the Pharmaceutical Benefits Scheme – information for patients
Page last updated: 6 August 2015
Crizotinib has been listed on the PBS via a Managed Entry Scheme (MES). This MES provides a mechanism to address the uncertainty over the size of the additional clinical benefit of this medicine while providing early access to those patients for whom there is a high clinical need.
Information about the benefits of this medicine in clinical practice will be collected, analysed and presented to the Pharmaceutical Benefits Advisory Committee (PBAC) for consideration in the near future.
Prescribers and patients must be aware that if a drug listed via a MES does not prove as beneficial in clinical practice as appeared in the clinical data presented to the PBAC, it may subsequently have its restriction modified, or may be removed from the PBS by the Commonwealth or at the request of the sponsor.
The relevant information for crizotinib is being collected about selected patients from their prescribing doctor. Patients are being selected on the grounds that they are crizotinib-naïve when initiating PBS supply. Selection will stop when there are enough patients providing the relevant information.
For more information on Managed Entry Schemes, please visit the 'Framework for the introduction of a Managed Entry Scheme for submissions to the Pharmaceutical Benefits Advisory Committee' page.
For more information on the PBAC’s consideration of this medicine and its MES, please see its Public Summary Document (PSD) from the November 2014 PBAC Meeting.